JP2021511331A5 - - Google Patents
Info
- Publication number
- JP2021511331A5 JP2021511331A5 JP2020539814A JP2020539814A JP2021511331A5 JP 2021511331 A5 JP2021511331 A5 JP 2021511331A5 JP 2020539814 A JP2020539814 A JP 2020539814A JP 2020539814 A JP2020539814 A JP 2020539814A JP 2021511331 A5 JP2021511331 A5 JP 2021511331A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- substituted
- acceptable salt
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023163639A JP2023169374A (ja) | 2018-01-19 | 2023-09-26 | 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ |
| JP2025065043A JP2025106500A (ja) | 2018-01-19 | 2025-04-10 | 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862619643P | 2018-01-19 | 2018-01-19 | |
| US62/619,643 | 2018-01-19 | ||
| US201862745724P | 2018-10-15 | 2018-10-15 | |
| US62/745,724 | 2018-10-15 | ||
| PCT/US2019/014344 WO2019144041A1 (en) | 2018-01-19 | 2019-01-18 | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023163639A Division JP2023169374A (ja) | 2018-01-19 | 2023-09-26 | 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021511331A JP2021511331A (ja) | 2021-05-06 |
| JP2021511331A5 true JP2021511331A5 (enExample) | 2022-01-25 |
| JP7401439B2 JP7401439B2 (ja) | 2023-12-19 |
Family
ID=65324663
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539814A Active JP7401439B2 (ja) | 2018-01-19 | 2019-01-18 | 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ |
| JP2023163639A Withdrawn JP2023169374A (ja) | 2018-01-19 | 2023-09-26 | 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ |
| JP2025065043A Pending JP2025106500A (ja) | 2018-01-19 | 2025-04-10 | 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023163639A Withdrawn JP2023169374A (ja) | 2018-01-19 | 2023-09-26 | 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ |
| JP2025065043A Pending JP2025106500A (ja) | 2018-01-19 | 2025-04-10 | 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ |
Country Status (33)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7438148B2 (ja) * | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7610985B2 (ja) * | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| WO2020227097A1 (en) * | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| RS65302B1 (sr) | 2019-07-17 | 2024-04-30 | Cytokinetics Inc | Oralne formulacije inhibitora srčanog sarkomera |
| EP3999180B1 (en) * | 2019-07-17 | 2024-05-08 | Cytokinetics, Inc. | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
| BR112022000523A2 (pt) * | 2019-07-17 | 2022-03-03 | Cytokinetics Inc | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica |
| MX2023002024A (es) | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| CN112094253B (zh) * | 2020-09-10 | 2023-01-10 | 株式会社大熊制药 | 用于制备sglt抑制剂中间体的合成方法 |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| MX2024001294A (es) | 2021-08-03 | 2024-02-13 | Cytokinetics Inc | Proceso para la preparacion de aficamten. |
| EP4514355A1 (en) | 2022-04-26 | 2025-03-05 | MyoKardia, Inc. | Methods of administering myosin inhibitors |
| WO2024020468A1 (en) | 2022-07-20 | 2024-01-25 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| EP4565230A1 (en) | 2022-08-04 | 2025-06-11 | Cytokinetics, Inc. | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024040190A1 (en) | 2022-08-18 | 2024-02-22 | Cytokinetics, Incorporated | Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors |
| WO2024134498A1 (en) | 2022-12-22 | 2024-06-27 | Assia Chemical Industries Ltd. | Solid state forms of aficamten and process for preparation thereof |
| CN115894361A (zh) * | 2022-12-28 | 2023-04-04 | 上海合全药业股份有限公司 | 一种钯催化合成1-乙酰基-6-氰基-四氢喹啉的方法 |
| WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| WO2025096779A2 (en) | 2023-11-01 | 2025-05-08 | Bristol Myers Squibb Company | Methods of treatment with a myosin inhibitor using protein levels |
| WO2025175141A1 (en) * | 2024-02-16 | 2025-08-21 | Cytokinetics, Incorporated | Fast skeletal muscle myosin inhibitors |
| US20250295639A1 (en) | 2024-03-20 | 2025-09-25 | Cytokinetics, Incorporated | Methods for treating heart diseases |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633499A (en) | 1899-06-29 | 1899-09-19 | Oil Well Supply Co | Coupling for pipes, tubes, or casings. |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6908923B2 (en) | 2001-12-21 | 2005-06-21 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| AU2002365057A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| AU2003247633A1 (en) * | 2002-06-24 | 2004-01-06 | Vivoquest, Inc. | BENZO(b)FURAN DIMERS |
| ATE552236T1 (de) * | 2003-01-14 | 2012-04-15 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz |
| AU2004206955A1 (en) | 2003-01-21 | 2004-08-05 | Archemix Corp. | Aptamer therapeutics useful in ocular pharmacotherapy |
| EP1605752B1 (en) | 2003-03-27 | 2011-09-14 | Cytokinetics, Inc. | Sulfonamides for the treatment of congestive heart failure, their compositions and uses. |
| JP2007516176A (ja) | 2003-06-20 | 2007-06-21 | アムジエン・インコーポレーテツド | ピペラジン誘導体及び使用方法 |
| ES2522579T3 (es) * | 2004-06-17 | 2014-11-17 | Cytokinetics, Inc. | Compuestos, composiciones y métodos |
| CN101137414A (zh) * | 2004-12-31 | 2008-03-05 | 欧兰拓制药股份有限公司 | 多环双酰胺mmp抑制剂 |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| TW200718692A (en) | 2005-04-22 | 2007-05-16 | Wyeth Corp | Dihydrobenzofuran derivatives and uses thereof |
| BRPI0609802A2 (pt) * | 2005-05-20 | 2017-05-02 | Alantos Pharmaceuticals Holding Inc | composto, composição farmacêutica e uso de um composto |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| WO2010033701A2 (en) * | 2008-09-19 | 2010-03-25 | Genzyme Corporation | Inhibitors of sphingosine kinase 1 |
| NZ596302A (en) | 2009-05-15 | 2014-01-31 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
| US8592426B2 (en) * | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| US9493412B2 (en) * | 2011-09-27 | 2016-11-15 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| US9409917B2 (en) | 2012-01-20 | 2016-08-09 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| AU2014362231B2 (en) | 2013-12-11 | 2019-04-04 | Biogen Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| WO2015142001A2 (ko) | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| KR20170103962A (ko) * | 2015-01-20 | 2017-09-13 | 머크 샤프 앤드 돔 코포레이션 | 인자 xia 억제제 |
| EP4234017B1 (en) | 2015-01-22 | 2026-04-15 | MyoKardia, Inc. | Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm) |
| CN105884752B (zh) * | 2015-02-13 | 2018-08-31 | 山东轩竹医药科技有限公司 | 并环类回旋酶和拓扑异构酶iv抑制剂 |
| CN108137517B (zh) | 2015-10-02 | 2022-04-12 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| JP2019507110A (ja) | 2015-12-17 | 2019-03-14 | シンジェンタ パーティシペーションズ アーゲー | 殺微生物性オキサジアゾール誘導体 |
| CN108368098B (zh) | 2015-12-18 | 2022-01-28 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| CA3022432A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
| WO2017222951A1 (en) | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| JP6681517B2 (ja) | 2016-09-27 | 2020-04-15 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ｍＧｌｕＲ２陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用 |
| WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| JP2020023442A (ja) | 2016-12-19 | 2020-02-13 | 住友化学株式会社 | オキサジアゾール化合物及び植物病害防除方法 |
| WO2018156883A1 (en) | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| CN110325517B (zh) | 2017-02-28 | 2021-03-02 | 南京明德新药研发有限公司 | 螺环类化合物及其应用 |
| CA3071948A1 (en) | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
| BR112022000523A2 (pt) | 2019-07-17 | 2022-03-03 | Cytokinetics Inc | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica |
| RS65302B1 (sr) | 2019-07-17 | 2024-04-30 | Cytokinetics Inc | Oralne formulacije inhibitora srčanog sarkomera |
| EP3999180B1 (en) | 2019-07-17 | 2024-05-08 | Cytokinetics, Inc. | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
| MX2023002024A (es) | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| MX2024001294A (es) | 2021-08-03 | 2024-02-13 | Cytokinetics Inc | Proceso para la preparacion de aficamten. |
| EP4514355A1 (en) | 2022-04-26 | 2025-03-05 | MyoKardia, Inc. | Methods of administering myosin inhibitors |
-
2019
- 2019-01-18 WO PCT/US2019/014344 patent/WO2019144041A1/en not_active Ceased
- 2019-01-18 HU HUE19703917A patent/HUE067913T2/hu unknown
- 2019-01-18 SI SI201930788T patent/SI3740481T1/sl unknown
- 2019-01-18 DK DK19703917.5T patent/DK3740481T5/da active
- 2019-01-18 FI FIEP19703917.5T patent/FI3740481T3/fi active
- 2019-01-18 HR HRP20241014TT patent/HRP20241014T2/hr unknown
- 2019-01-18 KR KR1020207023807A patent/KR102797441B1/ko active Active
- 2019-01-18 CN CN202311746636.6A patent/CN117924208A/zh active Pending
- 2019-01-18 SM SM20240329T patent/SMT202400329T1/it unknown
- 2019-01-18 MD MDE20201196T patent/MD3740481T3/ro unknown
- 2019-01-18 SG SG11202006296YA patent/SG11202006296YA/en unknown
- 2019-01-18 UY UY38057A patent/UY38057A/es active IP Right Grant
- 2019-01-18 NZ NZ765795A patent/NZ765795A/en unknown
- 2019-01-18 AU AU2019208331A patent/AU2019208331C1/en active Active
- 2019-01-18 PT PT197039175T patent/PT3740481T/pt unknown
- 2019-01-18 ES ES19703917T patent/ES2986630T3/es active Active
- 2019-01-18 JP JP2020539814A patent/JP7401439B2/ja active Active
- 2019-01-18 MA MA51620A patent/MA51620B1/fr unknown
- 2019-01-18 PL PL19703917.5T patent/PL3740481T3/pl unknown
- 2019-01-18 CN CN201980009128.5A patent/CN111757875B/zh active Active
- 2019-01-18 EP EP24179234.0A patent/EP4491622A3/en active Pending
- 2019-01-18 CA CA3087283A patent/CA3087283C/en active Active
- 2019-01-18 RS RS20241047A patent/RS66042B9/sr unknown
- 2019-01-18 BR BR112020014428-2A patent/BR112020014428A2/pt active Search and Examination
- 2019-01-18 CN CN202311746655.9A patent/CN117964573B/zh active Active
- 2019-01-18 LT LTEPPCT/US2019/014344T patent/LT3740481T/lt unknown
- 2019-01-18 CA CA3252332A patent/CA3252332A1/en active Pending
- 2019-01-18 MX MX2020007532A patent/MX2020007532A/es unknown
- 2019-01-18 TW TW113106914A patent/TWI898447B/zh active
- 2019-01-18 MY MYPI2020003691A patent/MY203855A/en unknown
- 2019-01-18 TW TW108101933A patent/TWI835770B/zh active
- 2019-01-18 EP EP19703917.5A patent/EP3740481B9/en active Active
- 2019-01-18 US US16/252,483 patent/US10836755B2/en active Active
-
2020
- 2020-07-14 MX MX2022014312A patent/MX2022014312A/es unknown
- 2020-07-14 CL CL2020001871A patent/CL2020001871A1/es unknown
- 2020-07-16 PH PH12020551090A patent/PH12020551090A1/en unknown
- 2020-07-16 IL IL276094A patent/IL276094B2/en unknown
- 2020-07-27 CO CONC2020/0009225A patent/CO2020009225A2/es unknown
- 2020-07-31 EC ECSENADI202044709A patent/ECSP20044709A/es unknown
- 2020-09-04 US US17/013,472 patent/US11472796B2/en active Active
-
2022
- 2022-04-28 CL CL2022001091A patent/CL2022001091A1/es unknown
- 2022-08-31 US US17/823,910 patent/US12065436B2/en active Active
-
2023
- 2023-09-26 JP JP2023163639A patent/JP2023169374A/ja not_active Withdrawn
-
2024
- 2024-07-02 US US18/762,390 patent/US20250059173A1/en active Pending
- 2024-07-15 AU AU2024204859A patent/AU2024204859A1/en active Pending
-
2025
- 2025-04-10 JP JP2025065043A patent/JP2025106500A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511331A5 (enExample) | ||
| IL276094B2 (en) | Dihydrobezofuran and indan analogues as cardiac sarcomere inhibitors | |
| JP2021529185A5 (enExample) | ||
| JP2021535164A5 (enExample) | ||
| JP5702392B2 (ja) | キサンチンオキシダーゼ阻害剤として効果的な新規化合物、その製造方法及びそれを含有する医薬組成物 | |
| JP2024508526A5 (enExample) | ||
| CN115244056A (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| EP2639229B1 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| JP2022508203A5 (enExample) | ||
| JP2021529746A5 (enExample) | ||
| JP2002529532A5 (enExample) | ||
| CA2498559A1 (en) | Indole derivatives or benzimidazole derivatives for modulating i.kappa.b kinase | |
| WO2009145360A1 (en) | Benzene or thiophene derivative and use thereof as vap-1 inhibitor | |
| JP2022540668A5 (enExample) | ||
| JP2018531982A5 (enExample) | ||
| JP2012505891A5 (enExample) | ||
| TW201031645A (en) | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | |
| JP2022542803A5 (enExample) | ||
| JPS59118783A (ja) | 新規の置換された１，４−ジヒドロピリジン、その製造法及びこれを診断剤として使用する方法 | |
| KR101726819B1 (ko) | Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 | |
| JP2020527149A5 (enExample) | ||
| CN106459026B (zh) | 制备pde10抑制剂的方法和中间体 | |
| WO2012124311A1 (ja) | 新規なフェニルピリジン誘導体及びこれを含有する医薬 | |
| JPWO2011024468A1 (ja) | 新規なスルホンアミド誘導体及びこれを含有する医薬 | |
| JPS61143378A (ja) | １，４‐ジヒドロピリジン、その製造法及びその使用法 |